Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could simple education tame myeloma Treatment's harsh side effects?

NCT ID NCT07774988

Symptom relief Sponsor: Can Lafci Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This trial tests whether personalized education from a nurse can help people newly diagnosed with multiple myeloma better handle side effects from the drug bortezomib. Participants receive either standard care or two one-on-one teaching sessions covering symptoms like nerve pain, fatigue, and nausea. The study tracks how severe these symptoms become over about two months to see if education makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Individualized nurse-delivered education program
What this could lead to
If effective, this education program could become a standard part of care to help myeloma patients better manage treatment side effects and improve their quality of life.
What could go wrong
The trial is small and early, so results may not apply broadly. Education may not significantly reduce symptoms, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

49 people

The number who actually took part.

Started

Feb 2018

Finished

Aug 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Newly diagnosed with multiple myeloma * Scheduled to receive bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 * Able to communicate * Able to read and write * Willing to participate in the study Exclusion Criteria: * Younger than 18 years * Presence of a disease or condition that could affect the nervous system, such as brain metastasis or diabetes * Cognitive impairment * Unstable vital signs * History of alcohol use * Communication impairment * Unwilling to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Ege University Faculty of Medicine, Berna Türek Chemotherapy Center

    İzmir, Istanbul, 34854, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.